Dr. AMendel et al:TMP-SMX prophylaxis assoc w⬇️serious infexns in RTX treated GPA pts; BL (aHR 0.5;95%CI 0.3-0.8) & time-varying exposure (aHR 0.5; 95%CI 0.3-0.9) A good thing to consider but weigh benefits/harms w/TMP-SMX prophy. More studies req'd? #ACR23 ABST1584 @RheumNow https://t.co/dfsfpcQu2A

Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw

TMP-SMX in AAV with RTX. 919 patients. Only given to 31% (40% on steroid>20mg), what!? TMP-SMX aHR 0.5 for serious infection, aHR 0.7 for minor infection. PJP 13 vs 0. Abstr#1584 #ACR23 @RheumNow https://t.co/4YQELIC82F https://t.co/U5l5KzSkB5

MOSAIC study: #ACR23 Abs #1690 finds APR reduces clinical and objective MRI indices in PsA, confirming an effect of APR on clinical and inflammatory manifestations of PsA. https://t.co/F5D81FF1tj @rheumnow https://t.co/rGglgiOyDg

TMP-SMX PPx in GPA A#1584 @RheumNow #ACR23 919 pt analyzed TMP-SMX ass w/ decr serious ifn (HR 0.5), less outpt ifns (0.9) Rates for AEs attrib to TMP-SMX per 100 py: 29.6, wo TMP-SMX: 13.4 13 PJP, all in non-TMP-SMX pts Should we use Bactrim to prevent ifn beside PJP? GC effects

#ACR23 Abstr#1584 Data N=919 pts with GPA vasculitis treated with rituximab showed Septrin prophylaxis (+/- 28days of RTX) reduced serious & any infection. PJP=1.4% not on septrin. Question remains re: how long for in those receiving repeat cycles & steroid confounding @RheumNow https://t.co/81f8hbMids

What is frailty? How does it affect RA outcomes? Pop based cohort study 13000+ RA vs. 26000+ matched ctrl Over 2x more frailty 5.6% vs 2.6% OR frailty in RA 2.3 Adjusted for rurality, neighborhood income quartiles AND BL comorbidities index @RheumNow #ACR23 ABST1275 https://t.co/ZkOpgHPSE0

17% of 1st degree relatives AS pts had MRI- defined sacroiliitis, however not all of them were diagnosed w/ SpA due to absence of back pain. 25% w/ 1st degree AS relative met the classification criteria for SpA #ACR23 Abs #1403 https://t.co/W1T9ZqD4o1 @rheumnow https://t.co/DnaNSLiqfU

SMART study #ACR23 Plenary abs #1583: po split-dose MTX (vs single dose) once weekly in RA pts had ^^ efficacy & reduced need for add'l DMARDs. No major AE, but slight increase in frequency of persistent transaminitis in split-dose group. https://t.co/wHzjpSnfuA @rheumnow https://t.co/0hNTMGbt47

Large VA study of >1k RA-ILD pts No difference in risk of respiratory hospitalization or death in RA-ILD pts using TNFi vs. nonTNFi/JAKi Data does not support avoiding TNFi in RA-ILD @RheumNow #ACR23 Abs#1582 https://t.co/LTNLXEIAPo

Ab#1582 @RheumNow #ACR23 RA-ILD outcomes of TNFi v non-TNF b/tsDMARD VA Data, propens match emulation study No incr risk of death in TNFi vs non-TNFi But are TNF safe? - Don't support systematic avoidance. But are there specific pops - unsure. Don't answer if efficacy in RA-ILD https://t.co/AApEjZs4DM

Important plenary session, RA-ILD outcomes in VA cohort study No difference in death/hospitalization for TNF vs non-TNF treated patients. Jives w/my priors; I do NOT avoid TNF in RA-ILD Encouraging if you (like me) prefer RA-active tx for RA-ILD 😉😆 @RheumNow #ACR23 #ACRBest https://t.co/TIDzMLOfs4

World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK involvement vs ljSSc pts w/ more cardiac involvement. No significant differences in ILD, PAH, GI involvement. #ACR23 Abs #1623 https://t.co/czAH0hpY2a @rheumnow https://t.co/RcfAJORXY3